Follow us on Twitter
twitter icon@FreshPatents

Browse patents:
Next
Prev

Piperidine derivatives useful as modulators of chemokine receptor activity




Title: Piperidine derivatives useful as modulators of chemokine receptor activity.
Abstract: and the remaining variables are defined herein. The present invention also relates to a process for preparing such compounds and use of such compounds in the treatment of a chemokine (such as CCR3) or H1 mediated disease state. in which: The present invention relates to the compounds of formula (I): ...


- Minneapolis, MN, US
USPTO Applicaton #: #20090069325
Inventors: Christopher Luckhurst, Matthew Perry, Hitesh Sanganee, Brian Springthorpe


The Patent Description & Claims data below is from USPTO Patent Application 20090069325, Piperidine derivatives useful as modulators of chemokine receptor activity.

Advertise on FreshPatents.com - Rates & Info


You can also Monitor Keywords and Search for tracking patents relating to this Piperidine derivatives useful as modulators of chemokine receptor activity patent application.

###

Keyword Monitor How KEYWORD MONITOR works... a FREE service from FreshPatents
1. Sign up (takes 30 seconds). 2. Fill in the keywords to be monitored.
3. Each week you receive an email with patent applications related to your keywords.  
Start now! - Receive info on patent apps like Piperidine derivatives useful as modulators of chemokine receptor activity or other areas of interest.
###


Previous Patent Application:
N-formyl hydroxylamine derivatives as inhibitors of bacterial polypeptide formylase for treating microbial infections
Next Patent Application:
Substituted pyrrolidinones as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
Industry Class:
Drug, bio-affecting and body treating compositions
Thank you for viewing the Piperidine derivatives useful as modulators of chemokine receptor activity patent info.
- - -

Results in 0.05144 seconds


Other interesting Freshpatents.com categories:
Medical: Surgery Surgery(2) Surgery(3) Drug Drug(2) Prosthesis Dentistry  

###

Data source: patent applications published in the public domain by the United States Patent and Trademark Office (USPTO). Information published here is for research/educational purposes only. FreshPatents is not affiliated with the USPTO, assignee companies, inventors, law firms or other assignees. Patent applications, documents and images may contain trademarks of the respective companies/authors. FreshPatents is not responsible for the accuracy, validity or otherwise contents of these public document patent application filings. When possible a complete PDF is provided, however, in some cases the presented document/images is an abstract or sampling of the full patent application for display purposes. FreshPatents.com Terms/Support
-g2-0.0587

66.232.115.224
Browse patents:
Next
Prev

stats Patent Info
Application #
US 20090069325 A1
Publish Date
03/12/2009
Document #
File Date
12/31/1969
USPTO Class
Other USPTO Classes
International Class
/
Drawings
0




Follow us on Twitter
twitter icon@FreshPatents

Astrazeneca Ab



Drug, Bio-affecting And Body Treating Compositions   Designated Organic Active Ingredient Containing (doai)   Heterocyclic Carbon Compounds Containing A Hetero Ring Having Chalcogen (i.e., O,s,se Or Te) Or Nitrogen As The Only Ring Hetero Atoms Doai   Hetero Ring Is Six-membered And Includes At Least Nitrogen And Oxygen As Ring Hetero Atoms (e.g., Monocyclic 1,2- And 1,3-oxazines, Etc.)   Morpholines (i.e., Fully Hydrogenated 1,4- Oxazines)   Additional Hetero Ring Attached Directly Or Indirectly To The Morpholine Ring By Nonionic Bonding   Ring Nitrogen In The Additional Hetero Ring  

Browse patents:
Next
Prev
20090312|20090069325|piperidine derivatives useful as modulators of chemokine receptor activity|and the remaining variables are defined herein. The present invention also relates to a process for preparing such compounds and use of such compounds in the treatment of a chemokine (such as CCR3) or H1 mediated disease state. in which: The present invention relates to the compounds of formula (I): |Astrazeneca-Ab
';